NCT01442610View on ClinicalTrials.gov

Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

September 30, 2015

Conditions
Sleep DisturbancesParkinsons's Disease
Interventions
DRUG

Rasagiline

Rasagiline tablets 1mg once daily for 8 weeks

DRUG

Placebo

Placebo 1tablet once daily for 8 weeks

Trial Locations (1)

01307

Dresden University of Technology, Dept. of Neurology, Dresden

All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

Technische Universität Dresden

OTHER

NCT01442610 - Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease | Biotech Hunter | Biotech Hunter